AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
BMC Infect Dis. 2023 Jun 20;23(1):418. doi: 10.1186/s12879-023-08402-w.
In vitro diagnostics (IVDs) for primary detection test/screening of human T-cell leukemia virus (HTLV) have recently been updated to new-generation products in Japan. In this study, the performance of these products was evaluated and discussed in terms of the usability of HTLV diagnosis in Japan.
The performance of 10 HTLV IVDs for primary detection test and confirmatory/discriminatory test was evaluated. Plasma specimens that had been declared ineligible for transfusion were provided by the Japanese Red Cross Blood Center.
The diagnostic specificity of the IVDs was 100% (160/160). Six sandwich assays resulted in all HTLV-1/HTLV-positive specimens being positive (46/46). On the other hand, one sandwich assay, IVD under development 2 (UD2), resulted in one HTLV-1-positive and one HTLV-positive specimen being negative (44/46, 95.7%). One indirect assay, HISCL HTLV-1, could not detect one HTLV-positive specimen (45/46, 97.8%), but the updated product, UD1, correctly detected it (46/46, 100%). Serodia HTLV-I, based on a particle agglutination assay, resulted in 44 of the 46 positive specimens, but could not detect two specimens (44/46, 95.7%). ESPLINE HTLV-I/II, based on an immunochromatography assay (ICA), was able to diagnose all specimens as positive (46/46, 100%).
Six sandwich assays and an ICA demonstrated high diagnostic sensitivity and specificity and are recommended for use in HTLV diagnosis in conjunction with confirmatory/discriminatory test using the INNO-LIA HTLV-I/II Score.
日本最近更新了用于人类 T 细胞白血病病毒 (HTLV) 初次检测/筛查的体外诊断试剂 (IVD)。本研究评估了这些产品的性能,并就其在日本 HTLV 诊断中的可用性进行了讨论。
评估了 10 种用于初次检测和确认/鉴别试验的 HTLV IVD 的性能。提供的血浆标本来自日本红十字会血液中心,这些标本被宣布不适合输血。
IVD 的诊断特异性为 100%(160/160)。6 种夹心检测法均导致所有 HTLV-1/HTLV-阳性标本均为阳性(46/46)。另一方面,一种夹心检测法,即正在开发的 IVD2(UD2),导致 1 份 HTLV-1 阳性和 1 份 HTLV 阳性标本为阴性(44/46,95.7%)。一种间接检测法,即 HISCL HTLV-1,无法检测到 1 份 HTLV 阳性标本(45/46,97.8%),但更新后的产品 UD1 则能正确检测到(46/46,100%)。基于粒子凝集检测法的 Serodia HTLV-I 可检测到 46 份阳性标本中的 44 份,但无法检测到 2 份标本(44/46,95.7%)。基于免疫层析法(ICA)的 ESPLINE HTLV-I/II 可诊断所有标本均为阳性(46/46,100%)。
6 种夹心检测法和 ICA 显示出较高的诊断敏感性和特异性,建议与 INNO-LIA HTLV-I/II Score 联合使用,作为 HTLV 诊断的确认/鉴别试验。